Kv2.1 Channel-Derived Peptides for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cerebral ischemia and central nervous system trauma lack effective neuroprotective measures to inhibit the apoptotic potassium current surge mediated by Kv2.1 channels, which contributes to neuronal damage and death.
Innovation Solution
Development of isolated or recombinant Kv2.1 polypeptides and fusion proteins that disrupt the binding of Kv2.1 to syntaxin, specifically targeting the C1a domain, to inhibit the apoptotic potassium current surge and prevent neuronal damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If Kv2.1 channels are blocked to inhibit apoptotic potassium current surge, then neuronal damage is reduced, but normal neuronal electrophysiological properties may be affected
Solution Approach 1:
The patent segments the Kv2.1 channel into specific functional domains (C1a, C1b, C2) and targets only the C1a domain for disruption. By using domain-specific peptides that bind to syntaxin at the C1a region, the invention selectively inhibits apoptotic potassium current surge while preserving the channel's normal voltage-dependent activation and repolarization functions, thus resolving the contradiction between preventing neuronal damage and maintaining normal electrophysiology
Solution Approach 2:
The invention applies local quality by targeting a specific local region (C1a domain) of the Kv2.1 channel for disruption. The peptides are designed to bind specifically to the syntaxin interaction site at residues 459-473 of the C1a domain, creating a localized interference that prevents apoptotic current surge without affecting the overall channel function or other domains (C1b, C2) that regulate normal electrophysiological properties
2Object-affected harmful factors
If peptide therapy is used to disrupt Kv2.1-syntaxin binding, then apoptotic potassium current surge is inhibited, but the complexity of treatment protocols increases
Solution Approach 1:
The patent extracts the critical syntaxin-binding function from the full Kv2.1 channel by using isolated C1a domain peptides. These minimal peptides ( SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76) contain only the essential residues (459-473) needed for syntaxin binding, allowing them to selectively disrupt the apoptotic current surge without requiring complex multi-component therapies
Solution Approach 2:
The invention utilizes parameter changes by modifying the peptide sequences at critical positions within the C1a domain. Specific amino acid substitutions (e.g., at residues 469-473) enhance the peptides' ability to bind syntaxin and disrupt the apoptotic current surge. By optimizing these sequence parameters, the therapy achieves high efficacy with simplified peptide designs, reducing treatment protocol complexity
Data Source
AI summary
Peptides capable of interfering with the Kv2.1-mediated apoptotic K+ current surge that leads to neuronal cell death are described. The disclosed peptides are derived from the C-terminal region of Kv2.1, which mediates binding to the SNARE protein syntaxin. Disruption of Kv2.1 binding to syntaxin inhibits the apoptotic K+ current surge that leads to neuronal cell death. The present disclosure provides methods of inhibiting binding of Kv2.1 to syntaxin in a cell (in vitro or in vivo), such as for neuroprotection following cerebral ischemia, stroke, or traumatic brain injury, or during the course of a neurodegenerative disease, or any other condition associated with neuronal cell death.